Clinical trial
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic…
NCT00154102 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00154102 |
|---|---|
| Title | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) |
| Official title | Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer |
| Acronym | CRYSTAL |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) |
| Enrollment | 1,221 |
| Start date | May 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Mar 1, 2011 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 30, 2017 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Czechia, Finland, France, Germany, Greece and 18 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: